Advances in the studies on the blood pressure effects and mechanisms of glucagon-like peptide 1 and glucagon-like peptide 1 receptor agonists
10.3760/cma.j.cn311282-20200217-00071
- VernacularTitle:胰升糖素样肽1与胰升糖素样肽1受体激动剂的血压效应及作用机制的研究进展
- Author:
Lixin DING
1
Author Information
1. 高新人民医院内分泌科，宝鸡 721000
- From:
Chinese Journal of Endocrinology and Metabolism
2020;36(9):811-816
- CountryChina
- Language:Chinese
-
Abstract:
As a new class of hypoglycemic agents, the blood pressure effects of glucagon-like peptide 1 receptor agonists(GLP-1RAs)have been paid more and more attention. In animal experiments, the effects on blood pressure vary both acutely and with chronic administration. Clinical series of studies have confirmed the blood-lowering effect of GLP-1RAs administered chronically, and the antihypertensive effects of different GLP-1RAs appeared to be no significantly different. Brain stem nuclei, heart, kidney, and vascular endothelial cells might be involved in the mechanism underlying the effects on blood pressure. This paper reviews the blood pressure effects and mechanisms of glucagon-like peptide 1 and GLP-1RAs in animals as well as its clinical effects.
